Continuous low-dose progestagen oral contraceptives

1974 ◽  
Vol 12 (3) ◽  
pp. 9-11
Keyword(s):  
Liver Function ◽  
Oral Contraceptives ◽  
Low Dose ◽  
Plasma Lipids ◽  
Metabolic Changes ◽  
Planned Parenthood ◽  
Carbohydrate Tolerance ◽  
British Committee

Combined oestrogen-progestagen contraceptives, usually taken for three weeks out of four, are effective in preventing pregnancy. The small risks of thrombosis and embolism are on the whole decreased with reduced doses of oestrogen.1 The use of the combined pill is also associated with a number of metabolic changes, including marginal impairment of carbohydrate tolerance and of liver function and an increase in some plasma lipids. Most of these metabolic changes are produced by the oestrogen component, and recent studies suggest that the progestagen is relatively inactive in this respect.2 The British Committee on Safety of Medicines and the Medical Committee of the International Planned Parenthood Federation now recommend that the combined preparations should not contain more than 50 mcg (0.05 mg) of oestrogen.

Liver function tests and low-dose estrogen oral contraceptives

Contraception ◽  
1980 ◽  
Vol 22 (6) ◽  
pp. 597-603 ◽  
Author(s):  
J. Dickerson ◽  
R. Bressler ◽  
C.D. Christian
Keyword(s):  
Liver Function ◽  
Oral Contraceptives ◽  
Low Dose ◽  
Liver Function Tests ◽  
Function Tests

EFFECTS OF COMBINED AND LOW-DOSE GESTAGEN ORAL CONTRACEPTIVES ON PLASMA LIPIDS; INCLUDING INDIVIDUAL PHOSPHOLIPIDS

1970 ◽  
Vol 63 (4) ◽  
pp. 717-735 ◽  
Author(s):  
U. Larsson-Cohn ◽  
R. Berlin ◽  
O. Vikrot
Keyword(s):  
Fatty Acids ◽  
Oral Contraceptives ◽  
Free Cholesterol ◽  
Low Dose ◽  
Plasma Lipids ◽  
Chlormadinone Acetate ◽  
One Year ◽  
The Individual ◽  
Combined Drugs ◽  
Testosterone Derivative

ABSTRACT Free fatty acids (FFA), triglycerides (TG), total and free cholesterol, total phospholipids and the individual phospholipids lysolecithin, sphingomyelin, lecithin and cephalin were determined in four groups of women, each consisting of nine or ten subjects. The determinations were performed before treatment and about every third month during one year of medication. Two combined drugs, Anconcene® (Chlormadinone acetate = CMA, 3 mg + mestranol 0.1 mg) and Conluten® (Norethindrone = NET, 2 mg + mestranol 0.1 mg) and two low-dose gestagen drugs, CMA 0.5 mg and NET 0.4 mg were used. FFA decreased in the Anconcene group. TG increased among those taking Anconcene, Conluten and NET. Slight increases of cholesterol were noted in the two groups taking combined drugs. Total phospholipids were increased in the Anconcene group and the Conluten group. Among the individual phospholipids, changes appeared similar to those found during pregnancy. They were most pronounced in the Anconcene group. It seems that it is the oestrogenic component of the combined drugs that is responsible for many of the alterations. It is suggested that the testosterone derivative NET but not the progesterone derivative CMA may have anti-oestrogenic effect in this connection.

Low-dose progesterone therapy in oestrogenised postmenopausal women: effects on plasma lipids, lipoproteins and liver function parameters

1993 ◽  
Vol 48 (1) ◽  
pp. 61-68 ◽  
Author(s):  
Ibrahim I. Bolaji ◽  
Helen Grimes ◽  
Gabriel Mortimer ◽  
Donald F. Tallon ◽  
Patrick F. Fottrell ◽  
...  
Keyword(s):  
Liver Function ◽  
Postmenopausal Women ◽  
Low Dose ◽  
Plasma Lipids

scholarly journals SUBCHRONIC TOXICITY TEST OF COMBINATION ETHANOL EXTRACT OF DETAM 1 SOYBEAN (GLYCINE MAX L. MERR) AND JATI BELANDA (GUAZUMA ULMIFOLIA LAMK) TOWARD FUNCTION, WEIGHT, AND HISTOPATHOLOGICAL OF WISTAR RAT LIVER

2016 ◽  
Vol 9 (5) ◽  
pp. 197
Author(s):  
Meilinah Hidayat ◽  
Sijani Prahastuti ◽  
Estherolita Dewi ◽  
Dewi Safitri ◽  
Siti Farah Rahmawati ◽  
...  
Keyword(s):  
Liver Function ◽  
Toxicity Test ◽  
Low Dose ◽  
Ethanol Extract ◽  
Good Effect ◽  
Control Group ◽  
High Dose ◽  
Subchronic Toxicity ◽  
Treatment Groups ◽  
Significant Difference

ABSTRACTObjective: As an antiobesity therapy, combination extracts of Detam 1 soybean and Jati Belanda will be consumed for a long time; therefore, theirtoxicities to the liver need to be investigated. To determine the effect of subchronic toxicity test of combination of ethanol extract of Detam 1 soybean(EEDS) and ethanol extract of Jati Belanda (EEJB) on liver function with parameters: Alanine transaminase (ALT), macroscopic, and histopathologicalof liver.Methods: This study was conducted on 120 Wistar rats (60 males and 60 females), 90 days (treatment group) and 120 days (satellite group). Ratswere divided into six treatment groups (3 test materials, 1 control, and 2 satellites); each group included 10 males and 10 females.Results: ALT levels of treatment groups (low dose, medium, and high), both males and females were lower than the control group (p<0.05). Thetreatment groups demonstrated a good effects effect on liver function. Liver weight of all groups showed no significant difference compared with thecontrol group (p>0.05). Results of histopathological score interpretation of male and female liver rats of low dose groups were not disturbed; middledose groups were slightly disturbed and high dose groups were damaged. Satellite high doses of male groups were disrupted, while female groupswere not.Conclusion: The combination of EEDS and EEJB has a good effect on liver function, did not lead to change organ weight and at low doses did not causerenal histopathology damage in rats after 90 days administration.Keywords: Combination of soybean Jati Belanda, Toxicity subchronic test, Function, Weight, Histopathology, Liver.

HAEMOSTATIC CHANGES INDUCED BY TWO LOW DOSE TRIPHASIC ORAL CONTRACEPTIVES

1987 ◽  
Author(s):  
S J Machin ◽  
I J Mackie ◽  
K Walshe ◽  
M D Gillmer
Keyword(s):  
Oral Contraceptives ◽  
Protein C ◽  
Low Dose ◽  
Factor Vii ◽  
Cycle Period ◽  
Factor Xii ◽  
Factor X ◽  
Combined Oral Contraceptives ◽  
First Time ◽  
Protein C Activity

The haemostatic system was investigated in 26 women taking cyclically administered triphasic combined oral contraceptives for the first time during their first six cycles. Fourteen women received Logynon (mean dose 32.4μg ethinyloestradiol, 92pg progestagen) and 12 received SHD 415G (Schering) which contains a mean dosage of 32.4μg ethinyloestradiol and 78pg gestodene, a recently developed progesterone. The Logynon group showed a significant increase (p<0.005) in fibrinogen (pre-mean 284.4 g/1; after 1 cycle 347.3 g/1, after 6 cycles 318.6 g/1) , factor VII (65.8 u/1 to 73.9 u/1 to 83.2 u/1), factor XII (1.74 u/1 to 2.41 u/1, to 2.25 u/1), plasminogen (100.9 u/1 to 135.1 u/1 to 126.3 u/1); decrease in ATIII (115.9 u/1 to 103.1 u/1 to 93.4 u/1) but no significant change in factor X (98.4 u/1 to 108.9 u/1 to 102.4) or protein C (0.85 u/1 to 0.88 u/1 to 0.94 u/1) activity. The SHD 415G group showed similar changes with an increase in fibrinogen (247.9 g/1 to 330.8 g/1 to 373 .1 g/1), factor VII (63.1 u/1 to 73.1 u/1 to 90.3 u/1, factor X (98.3 u/1 to 112.0 u/1 to 124.4 u/1), factor XII (1.46 u/1, to 1.93 u/1, to 2.03 u/1), plasminogen (110.8 u/1 to 125.4 u/1 to 136.7 u/1); decrease in ATIII (113.1 u/1 to 96.3 u/1 to 89.7 u/1), but no change in protein C (0.84 u/1 to - 0.78 u/1 to 0.85 u/1) activity. These changes were apparent after the first cycle of therapy and the differences were maintained over the six cycle period. There was no increase in protein C activity despite changes in the other vitamin K dependent proteins factors VII and X. Both low oestrogen dose triphasic pills caused similar prothrombotic changes which were not modified by the new progesterone, gestodene.

scholarly journals Association between the Current Use of Low-Dose Oral Contraceptives and Cardiovascular Arterial Disease: A Meta-Analysis

2005 ◽  
Vol 90 (7) ◽  
pp. 3863-3870 ◽  
Author(s):  
Jean-Patrice Baillargeon ◽  
Donna K. McClish ◽  
Paulina A. Essah ◽  
John E. Nestler
Keyword(s):  
Oral Contraceptives ◽  
Low Dose ◽  
Meta Analysis ◽  
Arterial Disease ◽  
Dose Oral

Association between efficacy and body weight or body mass index for two low-dose oral contraceptives

Contraception ◽  
2009 ◽  
Vol 79 (6) ◽  
pp. 424-427 ◽  
Author(s):  
Ronald T. Burkman ◽  
Alan C. Fisher ◽  
George J. Wan ◽  
Christopher E. Barnowski ◽  
Katherine D. LaGuardia
Keyword(s):  
Body Mass Index ◽  
Body Weight ◽  
Body Mass ◽  
Oral Contraceptives ◽  
Low Dose ◽  
Dose Oral
Sign in / Sign up

Export Citation Format

Share Document